Iliocaval Confluence Stenting for Chronic Venous Obstructions
- First Online:
- Cite this article as:
- de Graaf, R., de Wolf, M., Sailer, A.M. et al. Cardiovasc Intervent Radiol (2015) 38: 1198. doi:10.1007/s00270-015-1068-5
- 1.6k Downloads
Different techniques have been described for stenting of venous obstructions. We report our experience with two different confluence stenting techniques to treat chronic bi-iliocaval obstructions.
Materials and Methods
Between 11/2009 and 08/2014 we treated 40 patients for chronic total bi-iliocaval obstructions. Pre-operative magnetic resonance venography showed bilateral extensive post-thrombotic scarring in common and external iliac veins as well as obstruction of the inferior vena cava (IVC). Stenting of the IVC was performed with large self-expandable stents down to the level of the iliocaval confluence. To bridge the confluence, either self-expandable stents were placed inside the IVC stent (24 patients, SECS group) or high radial force balloon-expandable stents were placed at the same level (16 patients, BECS group). In both cases, bilateral iliac extensions were performed using nitinol stents.
Recanalization was achieved for all patients. In 15 (38 %) patients, a hybrid procedure with endophlebectomy and arteriovenous fistula creation needed to be performed because of significant involvement of inflow vessels below the inguinal ligament. Mean follow-up was 443 ± 438 days (range 7–1683 days). For all patients, primary, assisted-primary, and secondary patency rate at 36 months were 70, 73, and 78 %, respectively. Twelve-month patency rates in the SECS group were 85, 85, and 95 % for primary, assisted-primary, and secondary patency. In the BECS group, primary patency was 100 % during a mean follow-up period of 134 ± 118 (range 29–337) days.
Stenting of chronic bi-iliocaval obstruction shows relatively high patency rates at medium follow-up. Short-term patency seems to favor confluence stenting with balloon-expandable stents.
KeywordsDeep venous thrombosis Inferior vena cava Iliac vein Stent
Recanalization and stenting of chronic deep venous obstructions is a minimally invasive intervention that has proven effective and safe over the last decades . With low complication rates and substantial clinical improvement, this procedure has been increasingly performed over the last years. Long-term stent patency rates however vary substantially between clinical reports. Although encouraging 92 % stent patency after 10 years has been reported by dedicated high-volume centers [2, 3], lower results were published by clinics with lesser numbers of patients [4, 5]. Partly, this variation might be explained by lack in dedicated venous interventional tools, e.g., stents. However, in recent years, a lot has changed both in interventional materials and techniques, which might be vital to achieve an optimal result. Therefore, it is of great importance to report on experience with new developments in stent design and stenting technology to help establish an optimal protocol, both for defining the right indication and choosing the optimal treatment.
Chronic vena cava obstruction can stay asymptomatic for a long time. Extensive collateralization through paralumbar veins and the azygos system might obscure the underlying hemodynamic severity for many years into adulthood. However, many patients will be confronted with decompensation at some point in their life, which becomes clinically evident by acute, and in many cases bilateral deep venous thrombosis (DVT). Reconstruction of the occluded inferior vena cava (IVC) by means of angioplasty and stent placement has been performed previously with satisfactory to excellent results [6, 7, 8]. However, stenting of the common iliac vein confluence has only been thoroughly described by Neglén et al. . In their study, different stenting techniques were suggested to reconstruct the iliac confluence, all with their own limitations. In this article, we describe our experience with two confluence stenting techniques, one with merely self-expandable stents, the other with balloon-expandable stents bridging the common iliac vein confluence.
Materials and Methods
From November 2009 to August 2014, 741 patients were evaluated for chronic venous insufficiency/post-thrombotic syndrome (CVI/PTS) or acute central venous obstructive complaints at our tertiary medical center. Forty of these patients were diagnosed with chronic iliocaval obstruction. Chronic iliocaval obstruction was defined as 50 % or more venous lumen obstruction  of the IVC involving the confluence on Duplex ultrasound (DUS) or magnetic resonance venography (MRV) with presence of post-thrombotic trabecular changes in both common iliac and external arteries. All patients received DUS and MRV before treatment and cases were discussed in a multidisciplinary team consisting of a venous vascular surgeon, interventional radiologists, a dedicated ultrasonographer and experienced nurses.
All procedures were performed under general anesthesia and full anticoagulation. Patients were administered at least one dose of 5000 IU of heparin during the procedure. After the intervention, patients received a single dose of Low-Molecular-Weight Heparin (LMWH, Tinzaparine) and the pre-intervention anticoagulation regiment was continued, in general aiming for an international normalized ratio (INR) of 3.0–4.0. Patients who did not receive pre-interventional anticoagulation were started on coumarins directly post-stenting aiming for the same INR range, they received daily LMWH’s until this INR range was achieved (with a minimal treatment time of at least 5 days). When no underlying thrombophilia was proven, anticoagulation therapy was continued for at least 6 months.
Endophlebectomy and arteriovenous fistula creation
Extension of post-thrombotic changes at the level of the femoral vein inflow was seen in 15 (38 %) patients. The decision to perform adjunctive surgical desobstruction was pre-operatively made based on MRV imaging. When trabeculations were visible in the common femoral vein extending to both the femoral and the deep femoral (profunda) vein, peripheral venous inflow was deemed insufficient. Use of MRV imaging for evaluation of severity and extent of the disease (trabeculations) proofed consistent during surgery meaning desobstruction was performed in all the selected cases. In these 15 patients, a hybrid procedure consisting of endovascular recanalization and stenting combined with surgical groin incision, endophlebectomy, and creation of an arteriovenous fistula (AVF) was performed to optimize inflow and secure short-term stent patency. In the other 25 patients where no post-thrombotic changes at level of the deep femoral vein inflow were seen, merely recanalization and stenting was performed.
Post-operative stent patency was evaluated by DUS. All patients received follow-up according to a strict protocol consisting of DUS imaging 1 day post-intervention, 2 and 6 weeks after the intervention as well as 3, 6, and 12 months after the intervention and annually thereafter, or if recurrence of symptoms required earlier evaluation. Patency was defined as patency of more than 50 % of the venous lumen on DUS. Direct post-interventional as well as 2 and 6 week DUS examination enabled us to perform timely catheter-directed thrombolysis in case of acute re-occlusion.
Categorical data are presented by frequencies and percentages. Continuous data are expressed by mean or median values with range and standard deviation. Kaplan–Meier survival analysis was used to calculate patency rates per extremity for all patients (80 legs) as well as for the endovascular only group (50 legs); (Graphpad prism version 5.00 for Microsoft Windows, Graphpad Software. San Diego, CA). Survival percentages with a standard error of the mean (SEM) of >10 % were discarded as being unreliable.
Overview of CEAP clinical classification  for the study population (40 right and 40 left legs)
Acute bilateral DVT was the indication for treatment in 6 (15 %) patients, skin changes and ulceration in 18 (45 %) patients, venous claudication in 15 (38 %) patients, and chronic lower extremity pain without claudication in one (3 %) patient.
All 40 patients with iliocaval obstructions were recanalized successfully. The average length of vena cava occlusion was 13.8 (range 5–21) cm. The average total length of iliocaval obstruction was 31.2 cm (range 24–37). No per-procedural bleedings or other complications were encountered. In 24 patients, self-expandable stents were used to construct the confluence (SECS group), while in 16 patients a combination of balloon-expandable and self-expandable stents was used (BECS group).
Specific analysis of the population treated by endovascular means only (without endophlebectomy and AV-fistula creation) shows higher patency rates. Twelve-month patency rates in the SECS group were 85, 85, and 95 % for primary, assisted-primary, and secondary patency, respectively (Fig. 3B). In the BECS group, primary patency was 100 % during a mean follow-up period of 134 ± 118 (range 29–337) days (Fig. 3B).
Overview and quantification of complications observed in 40 patients treated with caval-bi-iliac recanalization and stenting
Reocclusion in one or both iliac veins or IVC
Significant stenosis due to AVF
Stenosis deemed non-hemodynamically significant
The etiology of IVC obstruction has not yet been determined completely. A congenital origin has been proposed . Central line placement and subsequent thrombosis in premature life might be another explanation . In the present study population, only two patients had endured such an intervention. Sudden IVC thrombosis in later life might develop in case of compression by benign or malignant masses or adjacent anatomic structures. However, we did not see such underlying pathology in our patient population. True absence of the IVC has also not been noticed in our group of 741 patients evaluated for signs of deep venous obstruction between 2009 and 2014. Although this might be suspected on angiography because no contrast dye is seen in the extent of the IVC, MRV always showed a visible remnant (Fig. 2A–C).
Iliac vein and IVC stenting has been performed successfully since more than a decade, has proven to be effective and is considered the first line of treatment in chronic venous obstructive disease . Nevertheless, experience was limited to a small number of centers for many years, with the group of Neglén et al. reporting on the largest number of patients by far [3, 9, 15]. Recently, recanalization and stenting of chronic venous obstructions became more widespread and probably will increase to mature in years to come. Although the endovenous approach has been suggested straightforward, innovative materials enable us to explore alternative approaches, which might reduce complications and improve results. Specifically, for confluence stenting, only few techniques and stent configurations have been proposed, mainly due to limitations in stent design. In the vast majority, the Wallstent™ (Boston Scientific®) was selected as the stent of choice, which limited stent configuration options. However, with the introduction of nitinol and cobalt–chromium stents appropriate for use in the venous system, other techniques have become available. We discuss our experience and patency results with these stents to treat bilateral iliocaval obstruction by means of confluence stenting.
We used two different techniques to construct the new confluence. In our earlier cases, we placed two self-expandable stents within a wide-diameter stent positioned in the distal vena cava just above the confluence, which were extended distally as far as required. With the help of per-procedural rotational angiography and coincidental CT examinations, it was noted though that stent compression was a main issue (Fig. 1). When two self-expandable stents are placed within a restricted space, one is likely to become greater in diameter than the other one, thereby compressing the contralateral side which is corroborated in the diminished short-term patency in the SECS group. Thus, we decided to optimize our protocol by bridging the confluence with two ultra-strong parallel positioned balloon-expandable stents. The BECS group showed a 100 % short-term primary patency. Although the present confluence technique has been mentioned before, no clear description of the technique and interventional tools were given. Furthermore, specific outcome data were not discussed .
There are some limitations to our study. First, the observational design of the study makes it difficult to draw strong conclusions toward the optimal confluence stent technique. However, availability of stents on the market precluded the possibility to perform a randomized design of the study. Nevertheless, our experience adds to the knowledge of venous stenting thus far reported and might aid in the process of product development and treatment protocols. Secondly, we used different stents to make peripheral extensions from the confluence toward the groin. In the beginning, we used nitinol closed-cell stents in the iliac veins. Since 2013, “dedicated venous stents” were used. “Dedicated” means that the stent manufacturer implies that the stent is better accommodated to the venous anatomy. Usually, these stents are larger in diameter, show good flexibility and high hoop force. Although these venous stents are supposed to perform better in the venous vasculature, up to now there is no proof that these stents improve outcome. Therefore, we have to conclude that the differences in patency between the SECS and BECS group are more likely based upon the configuration of confluence stenting. Based upon our experience with stenting across the common iliac vein confluence, we suggest preferable stenting technique to treat bilateral iliocaval obstructions. Preservation of bilateral symmetric inflow, protection of stent integrity, and avoidance of abundant stent material at the level of the confluence suggest that the BECS technique is superior to earlier described techniques. Evolution however is continuing, and we await the development of “confluence-stent” devices that have already been recognized in bifurcated aorta repair and might also support venous reconstructions.
Conflict of interest
Rick de Graaf reports personal fees from Optimed GmbH, personal fees from BARD GmbH/Angiomed, outside the submitted work. Mark de Wolf, Anna Sailer, Jorinde van Laanen have reported no conflict of interest. Cees Wittens reports personal fees from Optimed GmbH, research grants from EKOS, research grants from Sapheon, personal fees from MEDI, research grants from BoMedical, outside the submitted work. Houman Jalaie reports personal fees from Optimed GmbH, outside the submitted work.
Statement of Informed Consent
Informed consent was obtained from all individual participants included in the study; written informed consent was waived.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.